NCT05359861 2026-03-18
Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma
Coherus Oncology, Inc.
Phase 2 Completed
Clinical Trials
123 trialsNCT04300647 2026-03-12
SKYSCRAPER-04
Hoffmann-La Roche
Phase 2 Completed
NCT02705196 2026-02-24
LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer
Lokon Pharma AB
Phase 1/2 Completed
NCT04619797 2026-02-03
SKYSCRAPER-06
Hoffmann-La Roche
Phase 2/3 Completed
NCT04294810 2026-01-30
SKYSCRAPER-01
Hoffmann-La Roche
Phase 3 Completed
NCT04256421 2026-01-28
SKYSCRAPER-02
Hoffmann-La Roche
Phase 3 Completed
NCT03456063 2026-01-22
A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)
Hoffmann-La Roche
Phase 3 Completed
NCT03869190 2026-01-22
Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)
Hoffmann-La Roche
Phase 1/2 Completed
NCT03563716 2026-01-20
A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Genentech, Inc.
Phase 2 Completed
NCT04109456 2026-01-15
IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma
InxMed (Shanghai) Co., Ltd.
Phase 1 Completed
NCT04148911 2025-12-26
EL1SSAR
Hoffmann-La Roche
Phase 3 Completed
NCT03281369 2025-12-15
A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)
Hoffmann-La Roche
Phase 1/2 Completed
NCT03337698 2025-12-12
Morpheus Lung
Hoffmann-La Roche
Phase 1/2 Completed
NCT05908786 2025-12-11
A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma
Hoffmann-La Roche
Phase 1/2 Completed
NCT03735121 2025-12-05
A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT03193190 2025-11-21
A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Hoffmann-La Roche
Phase 1/2 Completed
NCT03371017 2025-11-12
IMpassion132
Hoffmann-La Roche
Phase 3 Completed
NCT04196530 2025-11-12
EIK1001
Eikon Therapeutics
Phase 1 Completed
NCT03280563 2025-11-10
MORPHEUS HR+BC
Hoffmann-La Roche
Phase 1/2 Completed
NCT04540211 2025-10-28
SKYSCRAPER-08
Hoffmann-La Roche
Phase 3 Completed
NCT04665843 2025-09-30
SKYSCRAPER-09
Hoffmann-La Roche
Phase 2 Completed
NCT03041311 2025-09-25
Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC
G1 Therapeutics, Inc.
Phase 2 Completed
NCT04487067 2025-09-22
AMETHISTA
Hoffmann-La Roche
Phase 3 Completed
NCT05459129 2025-09-15
A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)
Hoffmann-La Roche
Phase 1/2 Completed
NCT02500407 2025-09-12
A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Genentech, Inc.
Phase 1/2 Completed
NCT04513925 2025-09-08
SKYSCRAPER-03
Hoffmann-La Roche
Phase 3 Completed
NCT03568656 2025-08-08
Study to Evaluate CCS1477 in Advanced Tumours
CellCentric Ltd.
Phase 1/2 Completed
NCT02908672 2025-07-20
A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma
Hoffmann-La Roche
Phase 3 Completed
NCT05116202 2025-07-18
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)
Hoffmann-La Roche
Phase 1/2 Completed
NCT03502785 2025-07-10
INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma
Inovio Pharmaceuticals
Phase 1/2 Completed
NCT03289962 2025-07-04
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Genentech, Inc.
Phase 1 Completed
NCT05487235 2025-07-03
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Phase 1 Completed
NCT04975958 2025-06-22
Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors
Adlai Nortye Biopharma Co., Ltd.
Phase 1 Completed
NCT03473756 2025-04-09
FORT-2
Bayer
Phase 1 Completed
NCT03353831 2025-04-06
Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer
AGO Research GmbH
Phase 3 Completed
NCT04338269 2025-04-04
CONTACT-03
Hoffmann-La Roche
Phase 3 Completed
NCT05834348 2025-03-30
DELINOR
Pfizer
Completed
NCT02807636 2025-02-24
IMvigor130
Hoffmann-La Roche
Phase 3 Completed
NCT02876510 2025-02-04
ACTolog
Immatics US, Inc.
Phase 1 Completed
NCT02794571 2024-12-05
Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors
Genentech, Inc.
Phase 1 Completed
NCT02708680 2024-12-04
Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In
Syndax Pharmaceuticals
Phase 1/2 Completed
NCT03730012 2024-11-29
A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)
Astellas Pharma Inc
Phase 1/2 Completed
NCT03726879 2024-11-05
IMpassion050
Hoffmann-La Roche
Phase 3 Completed
NCT04096638 2024-10-31
Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors
invoX Pharma Limited
Phase 1 Completed
NCT04091217 2024-10-24
Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma
Hoffmann-La Roche
Phase 2 Completed
NCT03191786 2024-10-23
IPSOS
Hoffmann-La Roche
Phase 3 Completed
NCT04713891 2024-09-24
A Study of KF-0210 in Advanced Solid Tumors Patients
Keythera (Suzhou) Pharmaceuticals Co. Ltd
Phase 1 Completed
NCT02927301 2024-09-19
A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)
Genentech, Inc.
Phase 2 Completed
NCT04123470 2024-09-19
A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma
Lokon Pharma AB
Phase 1/2 Completed
NCT02594384 2024-08-22
LAM-002A/NHL
OrphAI Therapeutics
Phase 1 Completed